Terms: = Pancreatic cancer AND CIITA, P33076, 4261, ENSG00000179583, MHC2TA, C2TA
13 results:
1. A protein-based prognostic model for pancreatic ductal adenocarcinoma: Construction and validation.
Xu Y; Wang Y; Chen Q; Yao T; Qiu J; Ni L; Chen H; Liang T
Pancreatology; 2023 Dec; 23(8):1003-1013. PubMed ID: 37923686
[TBL] [Abstract] [Full Text] [Related]
2. Protection of cell therapeutics from antibody-mediated killing by CD64 overexpression.
Gravina A; Tediashvili G; Rajalingam R; Quandt Z; Deisenroth C; Schrepfer S; Deuse T
Nat Biotechnol; 2023 May; 41(5):717-727. PubMed ID: 36593395
[TBL] [Abstract] [Full Text] [Related]
3. Tumor cells fail to present MHC-II-restricted epitopes derived from oncogenes to CD4+ T cells.
Brightman SE; Naradikian MS; Thota RR; Becker A; Montero L; Bahmanof M; Premlal ALR; Greenbaum JA; Peters B; Cohen EE; Miller AM; Schoenberger SP
JCI Insight; 2023 Jan; 8(2):. PubMed ID: 36512410
[TBL] [Abstract] [Full Text] [Related]
4. Efficacy of EUS-guided FNB using a Franseen needle for tissue acquisition and microsatellite instability evaluation in unresectable pancreatic lesions.
Sugimoto M; Irie H; Takagi T; Suzuki R; Konno N; Asama H; Sato Y; Nakamura J; Takasumi M; Hashimoto M; Kato T; Kobashi R; Kobayashi Y; Hashimoto Y; Hikichi T; Ohira H
BMC Cancer; 2020 Nov; 20(1):1094. PubMed ID: 33176750
[TBL] [Abstract] [Full Text] [Related]
5. The RNA m6A methyltransferase METTL3 promotes pancreatic cancer cell proliferation and invasion.
Xia T; Wu X; Cao M; Zhang P; Shi G; Zhang J; Lu Z; Wu P; Cai B; Miao Y; Jiang K
Pathol Res Pract; 2019 Nov; 215(11):152666. PubMed ID: 31606241
[TBL] [Abstract] [Full Text] [Related]
6. Research on the epigenetic modification of pancreatic cancer vaccine.
Cao W; Zhou G; Qiu J; Xu L; Ding X; Zhang H; Zhou X
Hepatogastroenterology; 2014; 61(130):272-7. PubMed ID: 24901123
[TBL] [Abstract] [Full Text] [Related]
7. Epigenetically modified pancreatic carcinoma PANC-1 cells can act as cancer vaccine to enhance antitumor immune response in mice.
Tao Y; Lin F; Li T; Xie J; Shen C; Zhu Z
Oncol Res; 2013; 21(6):307-16. PubMed ID: 25198660
[TBL] [Abstract] [Full Text] [Related]
8. Epigenetic control of MHC class II expression in tumor-associated macrophages by decoy receptor 3.
Chang YC; Chen TC; Lee CT; Yang CY; Wang HW; Wang CC; Hsieh SL
Blood; 2008 May; 111(10):5054-63. PubMed ID: 18349319
[TBL] [Abstract] [Full Text] [Related]
9. First signature of islet beta-cell-derived naturally processed peptides selected by diabetogenic class II MHC molecules.
Suri A; Walters JJ; Rohrs HW; Gross ML; Unanue ER
J Immunol; 2008 Mar; 180(6):3849-56. PubMed ID: 18322192
[TBL] [Abstract] [Full Text] [Related]
10. Transfection of dendritic cells (DCs) with the ciita gene: increase in immunostimulatory activity of DCs.
Märten A; Ziske C; Schöttker B; Weineck S; Renoth S; Buttgereit P; Schakowski F; König S; von Rücker A; Allera A; Schroers R; Sauerbruch T; Wittig B; Schmidt-Wolf IG
Cancer Gene Ther; 2001 Mar; 8(3):211-9. PubMed ID: 11332992
[TBL] [Abstract] [Full Text] [Related]
11. Interferon regulatory factor-2 point mutations in human pancreatic tumors.
Xi H; Blanck G
Int J Cancer; 2000 Sep; 87(6):803-8. PubMed ID: 10956389
[TBL] [Abstract] [Full Text] [Related]
12. Co-occupancy of the interferon regulatory element of the class II transactivator (ciita) type IV promoter by interferon regulatory factors 1 and 2.
Xi H; Eason DD; Ghosh D; Dovhey S; Wright KL; Blanck G
Oncogene; 1999 Oct; 18(43):5889-903. PubMed ID: 10557076
[TBL] [Abstract] [Full Text] [Related]
13. HLA class II expression in uninducible hepatocarcinoma cells after transfection of AIR-1 gene product ciita: acquisition of antigen processing and presentation capacity.
Sartoris S; Valle MT; Barbaro AL; Tosi G; Cestari T; D'Agostino A; Megiovanni AM; Manca F; Accolla RS
J Immunol; 1998 Jul; 161(2):814-20. PubMed ID: 9670958
[TBL] [Abstract] [Full Text] [Related]
